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Objective: Genetic syndromes occur in more than 20% of patients with conotruncal heart defects. We investi-
gated the impact of genetic syndromes on the surgical outcome of conotruncal anomalies in infancy.
Methods: This retrospective study reviews the outcome of 787 patients (median age 6.3 months) who underwent
primary (598) or staged (189) repair of a conotruncal defect between 1992 and 2007.
Results: Proven genetic syndrome was diagnosed in 211 patients (26.8%), including del22q11 (91 patients), tri-
somy 21 (29 patients), VACTERL (18 patients), and other syndromes (73 patients). Primary repair was accom-
plished in 80.9% of nonsyndromic patients and 74.4% of syndromic patients (P ¼ .18) Fifteen-year
cumulative survival was 84.3%  2.3% in nonsyndromic patients and 73.2%  4.2% in syndromic patients
(P< .001). Primary and staged repair allowed similar 15-year survival (81.4%  4.5% vs 79.1%  5.1%,
P¼ .8). Freedom from noncardiac cause of death was significantly lower in syndromic patients (P¼ .0056). Fif-
teen-year Kaplan–Meier survival was 87.6%  3.9% for del22q11, 95.8%  4.1% for trisomy 21, 56.8% 
6.3% for VACTERL, and 62.3%  12.7% for patients with other syndromes (P ¼ .022). Total intensive care
unit stay was 10.8 4.9 days in syndromic patients and 5.1 1.7 days in nonsyndromic patients (P<.001). Free-
dom from reintervention 15 years after repair was 79.6% 4.9% in nonsyndromic patients and 62.4% 7.4% in
syndromic patients (P ¼ .007).
Conclusion:Del22q11 and trisomy 21 do not represent risk factors for mortality after repair of conotruncal anom-
alies, whereas other syndromes adversely affect the surgical outcome for predominant noncardiac attrition.
Higher morbidity and lower mid-term freedom from reintervention can be predicted in syndromic patients.Supplemental material is available online.
Genetic syndromes occur in more than 20% patients with
conotruncal heart defect (CTHD);1 nevertheless, the impact
of this association on the surgical outcome of the cardiac
anomalies is still incompletely defined. Previous studies
suggested that more than 17% of patients with CTHD carry
a 22q11 deletion.1,2 Moreover, trisomy 21 has been reported
in 7% of patients with tetralogy of Fallot (TOF).3 Patients
with TOF with Alagille syndrome carry a mutation in
JAG1,4 and VACTERL, CHARGE, or other syndromes
can be associated with TOF5 and other CTHDs.6 Patients
with CTHD and an associated genetic syndrome present
a challenge to the cardiac surgeon and may face additional
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doi:10.1016/j.jtcvs.2009.03.009The Journal of Thoracic andrisk for primary repair. This study was designed to document
the impact of genetic defects on the current surgical outcome
of CTHD.
MATERIALS AND METHODS
We reviewed the surgical and medical records of all patients who under-
went repair of a CTHD at Bambino Gesu` Hospital, Rome, Italy, between
January 1992 and January 2007. Informed parental consent and institutional
review board approval were obtained for this retrospective study. On the ba-
sis of the recommendations of Goldmuntz and colleagues,1 6 CTHDs were
included in this study because of their possible association with genetic de-
fects, specifically TOF, TOF pulmonary atresia (PA), TOF PA major aorto-
pulmonary collaterals (MAPCAs), truncus arteriosus (TA), double-outlet
right ventricle (DORV), and interrupted aortic arch (IAA). Posterior mala-
lignment-type ventricular septal defect (VSD) was not included because it
was always found to be associated with IAA in this cohort. Patients with
DORV and straddling atrioventricular (AV) valve, hypoplastic AV valve,
unbalanced ventricles, or heterotaxy syndromes were excluded because of
the rare option of a 2-ventricle repair in these malformation syndromes.
Patients with trisomy 13 and 18 also were excluded to avoid the bias of
the short and unfavorable natural history in these syndromes. Patients
who transferred their care to our unit, but were previously treated at other
centers, were excluded from this study. After informed parental consent,
a genetic consult by a clinical geneticist (M.C.D.) was obtained to rule
out the presence of a genetic syndrome, searching for dysmorphic features,
growth anomalies, mental retardation (>6 months of age), and associated
malformations. A blood sample was drawn for prospective chromosomal
analysis of peripheral lymphocytes using standard and high-resolution tech-
niques. Until 1994, search for microdeletion 22q11.2 relied on Southern
hybridization with HD7k probe detecting hemizygosity for the D22S134Cardiovascular Surgery c Volume 138, Number 3 565
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CTHD ¼ conotruncal heart defect
DORV ¼ double-outlet right ventricle
IAA ¼ interrupted aortic arch
MAPCAS ¼ major aortopulmonary collaterals
PA ¼ pulmonary atresia
RV ¼ right ventricle
RVOT ¼ right ventricular outflow tract
TA ¼ truncus arteriosus
TOF ¼ tetralogy of Fallot
VSD ¼ ventricular septal defect
region. After 1994, detection of deletions of chromosomal region 22q11
relied on fluorescent in situ hybridization using the Sc11.1 and N25 probe.
Screening was universal for del22q11 and selective for other genetic abnor-
malities (JAG1, NKX2.5, and others). Fluorescent in situ hybridization
analysis with the ENL probe was performed in subjects with clinical char-
acteristics of Williams syndrome. Analysis of medical records with clinical
descriptions of associated anomalies, prenatal and postnatal instrumental
investigations, and autoptic findings were obtained for the patients who
did not undergo genetic testing at birth. Preoperative 2-dimensional and
Doppler echocardiography were performed in all patients. Preoperative
cardiac catheterization was performed in 187 patients when pulmonary
arborization abnormalities such as discontinuous or hypoplastic pulmonary
artery branches, multiple aortopulmonary collaterals, presence of multiple
VSDs, or anomalous coronary artery patterns were suspected at echocardi-
ography. Cardiac catheterization allowed calculation of total neopulmonary
arterial index, pulmonary arterial index, and pulmonary artery-to-collateral
arteries lung segment perfusion ratio in the preoperative evaluation of
unifocalization and repair of TOF-PA-MAPCAs.7
Operative Technique
Complete repair was accomplished under hypothermic cardiopulmonary
bypass (25C–28C) for most CTHDs, whereas aortic arch reconstruction in
IAAwas achieved under deep hypothermic (18C) circulatory arrest. A sys-
temic-to-pulmonary shunt, if present, was divided. Ventricular septation
was accomplished through a transventricular approach in TA, TOF-PA-
MAPCAs, and occasionally in DORV, whereas a transatrial approach
was preferred in TOF and IAA. VSD closure with 1-stage unifocalization
in TOF-PA-MAPCAs was guided by an intraoperative pulmonary flow
study. Relief of right ventricular outflow tract (RVOT) obstruction in
TOF and DORV was achieved through a combined transatrial-transpulmo-
nary approach. RVOT reconstruction was accomplished after calibration of
the pulmonary annulus and PA branches. Preservation of the pulmonary an-
nulus by complete transatrial repair or limited infundibular patch plasty was
accomplishedwhen the Z-score for pulmonary annulus diameter was at least
–2. Transannular patching was used when the pulmonary annulus Z-score
was less than –2. Conduit interposition between the right ventricle (RV)
and the pulmonary confluence was used when indicated (PA, truncus). As-
sociated anomalies were corrected simultaneously. RV pressure and PA sat-
uration were measured after discontinuation of cardiopulmonary bypass to
detect residual outflow obstruction and left-to-right shunting. Intraoperative
transesophageal echocardiography was performed when residual lesions
were suspected after repair.
Follow-up
All surviving patients were followed in the pediatric cardiology outpa-
tient clinic. Clinical examination, 12-lead electrocardiogram, and 2-dimen-
sional echocardiography were performed at regular intervals to estimate566 The Journal of Thoracic and Cardiovascular Sutricuspid valve and RV function/pressure and to detect residual lesions,
pulmonary artery branch stenosis, or residual aortic arch stenosis. He-
modynamically significant residual lesions were confirmed at cardiac cath-
eterization before surgical or interventional procedures. Closing time for
follow-up was June 2007. Mean follow-up was 62.1  23 months (range
6–178 months) and was complete and updated in 765 patients (97.2%).
Statistical Analysis
Statistical analysis was conducted with the SAS Statview 1998 statistical
software (SAS Institute Inc, Cary, NC). Chi-square analysis was used to
compare discrete variables between syndromic and nonsyndromic patients,
and continuous variables (expressed as mean  standard deviation) were
compared by unpaired t testing. Categoric analysis was conducted by chi-
square and Fisher’s exact tests. Freedom from time-related events was con-
ducted according to actuarial or Kaplan–Meier technique; the resulting
curves with 95% confidence limits were compared with log-rank testing,
and nomograms of the hazard function were obtained . Selected and separate
end points were defined as death, reoperation, or interventional procedure.
Early mortality was defined as death within 30 days from surgery or before
hospital discharge. Variables associated with an increased risk of death and
reoperation were assessed by univariate logistic regression, multiple logistic
regression, and Cox proportional risk multivariate analysis. To avoid colin-
earity among covariates, only mutually exclusive variables were entered in
the multivariate analysis. Therefore, all genetic syndromes were compacted
under the covariate ‘‘genetic syndrome.’’
RESULTS
Between January 1992 and January 2007, 787 consecu-
tive patients (438 male and 349 female) underwent primary
(598) or staged (189) repair for CTHD. Median age at repair
was 6.3 months (range 0.1–214 months)
Anatomy
Surgical anatomy included 540 patients with TOF
(68.6%), 58 patients with TOF-PA (7.4%), 63 patients
with TOF-PA-MAPCAs (8%), 45 patients with TA
(5.7%), 45 patients with DORV (5.7%), and 36 patients
with IAA (4.6%). Type A IAA was diagnosed in 9 patients,
type B IAA was diagnosed in 26 patients, and type C IAA
was diagnosed in 1 patient.
Genetic Syndromes
A clinical genetic evaluation was obtained in 755 of 787
patients (95.9%), including 667 of 697 survivors (95.6%)
and 88 of 90 nonsurvivors (97.7%). Enrollment was refused
in 7 patients. Blood was drawn for chromosomal analysis of
peripheral lymphocytes using standard and high-resolution
techniques in 733 of 787 patients (93.1%). Proven genetic
defect was diagnosed in 211 patients (26.8%), including
del22q11 (91 patients), trisomy 21 (29 patients), VACTERL
(18 patients), and other syndromes (73 patients). Approxi-
mately one third of syndromic patients with CTHDs carried
a rare genetic defect and were unsuitable for syndrome-spe-
cific analysis. This heterogeneous group of patients was
therefore arbitrarily defined as ‘‘other syndromes’’ to allow
for meaningful statistical analysis and included CHARGE
(15 patients), Noonan (11 patients), Cantrell’s (6 patients),
Kabuki (5 patients), Klippel Feil (4 patients), Turner (2rgery c September 2009
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(3 patients), Torell (1 patient), Goldenhar (3 patients), Sotos
(1 patient), Waardenburg (1 patient), Townes-Brocks (1 pa-
tient), cystic fibrosis (1 patient), residual branchial arch syn-
drome (1 patient), del 5 p (1 patient), del 8 p (1 patient), and
del 10 p (2 patients). Mosaic trisomy-22 (2 patients), trans-
location 21/17 (1 patient), chromosome 7 anomalies (1 pa-
tient), and duplication 18q (2 patients) with associated
dysmorphic features were demonstrated in 6 patients. Con-
tingency table plotting surgical anatomy versus type of ge-
netic syndrome is depicted in Table E1.
Preoperative Noncardiac Surgical Procedures
Thirty-seven patients (4.7%) underwent extracardiac sur-
gery before CTHD repair. A genetic syndrome was demon-
strated in 29 cases (78.4%). Twenty-one patients with
esophageal atresia underwent primary esophageal recon-
struction (14 patients), combined gastrostomy and cervical
esophagostomy-associated tracheoesophageal fistula liga-
tion in 1 patient or isolated gastrostomy in 3 patients. Other
noncardiac procedures before cardiac repair included
colostomy (10 patients), gastrostomy and tracheostomy (2
patients), ileostomy (2 patients), ventriculoperitoneal shunt-
ing (1 patient), and pyloroplasty with liver biopsy (1 pa-
tient).
Cardiac Repair
Complete 2-ventricle repair was achieved in 787 patients.
Primary repair of CTHD was accomplished in 598 patients
(76%), whereas staged repair was performed in 189 patients
(24%). Complete primary neonatal repair was accomplished
in 109 patients (13.8%). Staged repair was more common in
syndromic CTHD (54/211 ¼ 25.6%) compared with non-
syndromic CTHD (110/577 ¼ 19.1%), although this differ-
ence was not statistically significant (P ¼ .18), therefore
suggesting that presence of a genetic defect per se did not
represent an indication for surgical palliation. There was
no correlation between surgical strategy of primary or staged
repair and presence or absence of extracardiac lesions requir-
ing extracardiac surgery (Fisher’s exact test P value ¼ .25).
Mean age at repair was 6.8  3.2 months in syndromic pa-
tients and 5.9  2.7 months in nonsyndromic patients (P ¼
.28). Mean weight at repair was 4.9  1.1 kg in syndromic
CTHD and 6.3  2.4 kg in nonsyndromic CTHD (P<
.01). Intracardiac repair was associated with additional car-
diac surgical procedures in 149 patients (24.5%), including
central or branch PA plasty (74 patients), unifocalization of
MAPCAs (44 patients) closure of additional muscular VSD
(11 patients), VSD enlargement (1 patient), ligation of left
persistent superior vena cava to the left atrium (9 patients),
bidirectional Glenn anastomosis as part of one-and-a-half
ventricle repair (3 patients), resection of supramitral fibrous
ring (2 patients), correction of partially anomalous pulmo-
nary venous connection (1 patient), aortopulmonary windowThe Journal of Thoracic and Crepair (2 patients), ligation of a systemic-to-pulmonary col-
lateral (1 patient), and resection of subaortic fibromuscular
ring (1 patient).
Mortality
Overall mortality after repair of CTHD was 11.4% (90/
787). Hospital mortality was 6.6% (38/576) in nonsyn-
dromic patients and 16.6% in syndromic patients (35/211)
(Fisher’s exact test P value< .001). Seventeen additional
late deaths occurred at follow-up in 8 syndromic and 9 non-
syndromic patients. Fifteen-year Kaplan–Meier survival
was 84.3%  2.3% in nonsyndromic patients and 73.2%
 4.2% in syndromic patients (P< .001) (Figure 1). Pri-
mary and staged repair allowed similar 15-year survival in
this cohort (81.4  4.5 vs 79.1  5.1, P ¼ .8). Table 1 de-
picts overall mortality according to baseline cardiac anatomy
and type of genetic syndrome, therefore showing the control
for complexity. A significant difference in survival between
syndromic and nonsyndromic patients was demonstrated af-
ter repair of TOF, TOF/PA, TOF/PA/MAPCAs, IAA, and
TA. Causes of death in syndromic and nonsyndromic pa-
tients are depicted in Table E2 and classified in cardiac
and noncardiac mortality. Table 2 clearly indicates that 5-
year freedom from noncardiac cause of death was signifi-
cantly lower in syndromic patients. When the potential
risk factors for death, identified by univariate analysis (Table
E3), were entered in a Cox proportional hazard model, pres-
ence of a genetic syndrome and non-TOF diagnosis were
identified as independent predictors of mortality (Table
E4). Kaplan–Meier 15-year survival was again 79.8% 
5.6% in nonsyndromic patients without TOF compared
with 61.8%  7.4% in syndromic patients without TOF
(P ¼ .027) (Figure 2). A secondary analysis was conducted
on the group of 211 syndromic patients to verify the impact
of various genetic syndromes on surgical outcome. Fifteen-
year Kaplan–Meier survival was 95.8% 4.1% for trisomy
21, 87.6%  3.9% for del22q11, 56.8%  6.3% for
FIGURE 1. Kaplan–Meier survival plot in syndromic and nonsyndromic
patients after repair of CTHD.ardiovascular Surgery c Volume 138, Number 3 567
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.022) (Figure 3). Table E5 depicts the analytic description of
syndrome-specific outcome with 5-year survival for the
subgroup ‘‘other syndromes.’’ Table E5 shows that
CHARGE, Noonan, Alagille, and Cantrell syndromes
were associated with suboptimal 5-year survival. Primary
and staged repair allowed similar 15-year survival in the syn-
dromic subgroup (74.3%  5.1% vs 71.9%  12.8%, re-
spectively, P ¼ .17). Logistic regression confirmed that
del22q11 and trisomy 21 were inverse risk factors for death,
whereas VACTREL syndrome was a significant predictor of
mortality in the syndromic subgroup (Table E3).
Complications and Reinterventions
Contingency analysis demonstrated significantly higher
postoperative morbidity after CTHD repair in syndromic pa-
tients (chi-square P value ¼ .039), which accounted for
a longer intensive care unit stay compared with nonsyn-
dromic patients (10.8  4.9 days vs 5.1  1.7 days, respec-
TABLE 1. Comparison of 1- and 5-year survival in syndromic and
nonsyndromic patients stratified by cardiac anatomy
Survival Syndrome No syndrome
Log-rank
P value
TOF 1 y 90.8%  2.8% 97.1%  1.4% .0026
5 y 88.9%  3.1% 96.9%  1.7% .0012
TOF-PA 1 y 86.9%  5.7% 94.1%  4.6% .035
5 y 81.8%  6.2% 93.1%  5.4% .004
TOF-PA-
MAPCAs
1 y 86.7%  4.1% 91.5%  2.7% .039
5 y 74.2%  7.7% 85.4%  5.3% .033
Truncus 1 y 85.3%  4.1% 93.7%  3.3% .006
5 y 81.7%  6.2% 91.3%  3.9% .018
DORV 1 y 91.5%  4.9% 96.7%  3.1% NS
5 y 88.8%  5.9% 94.8%  4.1% NS
IAA 1 y 91.9%  4.9% 78.4%  5.4% .031
5 y 86.7%  6.1% 69.8%  8.7% .028
Totals 1 y 87.7%  2.4% 94.1%  1.1% .0013
5 y 84.8%  2.7% 93.7%  1.3% .0007
NS, Not significant. Survival with 95% confidence limits were compared by log-rank
testing.
TABLE 2. Five-year freedom from death in syndromic and
nonsyndromic patients, stratified by cardiac and noncardiac cause of
death
Syndrome No syndrome
Log-rank
P value
5-y freedom from
noncardiac mortality
88.7%  2.3% 97.5%  0.6% .0056
5-y freedom from cardiac
mortality
92.5%  2.1% 95.1%  1.6% NS
5-y freedom from death,
any cause
84.8%  2.7% 93.7%  1.3% .0007
NS, Not significant. Survival with 95% confidence limits were compared by log-rank
testing. Freedom from noncardiac cause of death was significantly lower in syndromic
patients.568 The Journal of Thoracic and Cardiovascular Sutively, P < .001). Further reoperations (131 patients) or
alternative catheter procedures with stent or device place-
ment (37 patients) were required in 168 patients (21.3%)
to address residual lesions as recurrent VSD (19 patients), re-
sidual RVOT or branch PA stenosis (34 patients), combined
RVOT obstruction and recurrent VSD (9 patients), or re-
placement of RV-to-PA conduit (8 patients). Additional pro-
cedures included modified-Konno operation for tunnel
subaortic stenosis (3 patients), Ross-Konno operation (2 pa-
tients), aortic root replacement (1 patient), mitral valve
plasty (1 patient), tricuspid valve plasty (1 patient), tracheal
patch plasty (1 patient), renal transplantation (1 patient), and
combined heart and renal transplantation (1 patient). Alter-
native catheter intervention included placement of perma-
nent pacemaker for aortic valve block (11 patient) or sinus
node dysfunction (1 patient), collateral embolization (8 pa-
tients), VSD closure with device (2 patients), or stent place-
ment for branch PA stenosis (17 patients). Freedom from
FIGURE 2. Kaplan–Meier survival plot in syndromic and nonsyndromic
patients with non-TOF CTHD. TOF, Tetralogy of Fallot.
FIGURE 3. Kaplan–Meier survival plot in syndromic patients stratified by
type of genetic syndrome.rgery c September 2009
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fied by presence or absence of genetic syndrome, was
79.6%  4.9% in nonsyndromic patients and 62.4 
7.4% in syndromic patients (P ¼ .007) (Figure 4).
DISCUSSION
Several genetic abnormalities are currently known to be
associated with CTHDs. Previous studies suggested that
a substantial number of patients with CTHD carry a 22q11
deletion. Goldmuntz and colleagues1 reported an incidence
of del22q11 in 50% of IAA cases, 34.5% of TA cases, and
15.9% of TOF cases. Approximately 40% of patients with
TOF-PA-MAPCAs carry a 22q11 deletion.7,8 Non-Di
George syndromes have been reported to occur in CTHDs,
including VACTERL, Alagille, Fryns, and Down syn-
drome.9,10 On the other hand, punctiform mutations, such
as transcription factor NKX2.5 mutations or ZFPM2/FOG2
gene mutations, have been identified in nonsyndromic
TOF.11,12 The growing identification of genetic causes for
well-known genetic syndromes and congenital heart defects
such as CTHD prompts the risk assessment of specific ge-
netic defects on surgical outcome of CTHD. This retrospec-
tive review demonstrates the impact of various genetic
syndromes on surgical outcome of CTHD in recent years.
In our cohort of 787 patients, a genetic syndrome was docu-
mented in 26.8%. Our analysis shows the following:
1. Fifteen-year survival was 84.3%  2.3% in nonsyn-
dromic CTHD and 73.2%  4.2% in syndromic
CTHD (P< .001). Freedom from noncardiac attrition
was lower in syndromic patients, mainly because of in-
fective complications. These findings entail the applica-
tion of specific protocols for antibiotic prophylaxis in
syndromic patients undergoing repair of CTHDs. Cox
proportional hazard multivariate analysis identified the
FIGURE 4. Kaplan–Meier freedom from reoperation after complete repair
of CTHD in syndromic and nonsyndromic patients.The Journal of Thoracic and Cpresence of a genetic syndrome and non-TOF diagnosis
as independent predictors of mortality. We previously re-
ported a lower 10-year survival in syndromic patients
with TOF compared with nonsyndromic TOF.13 In this
cohort, 15-year survival was significantly worse in syn-
dromic patients without TOF compared with nonsyn-
dromic patients without TOF, and this finding was
confirmed for the following anatomic subtypes: TOF/
PA, TOF/PA/MAPCAs, and TA. Protract ventilatory
support, prolonged intensive care unit stay, and associ-
ated extracardiac lesions can explain the worse outcome
in syndromic patients with CTHDs in our cohort. These
data are in agreement with the experience of Oostehof
and colleagues,14 who identified the presence of noncar-
diac anomalies as an independent risk factor for death
after IAA repair.
2. The novel finding of this analysis is that del22q11 and tri-
somy 21 were not identified as risk factors for death after
repair of CTHDs. Long-term survival in del22q11 and
trisomy 21 was comparable with long-term outcome in
nonsyndromic CTHDs. These data are in agreement
with the experience of Rajasinghe and colleagues15 and
Williams and colleagues,16 who did not identify Di
George syndrome as a risk factor for mortality after repair
of persistent TA. Seifert and colleagues17 recently re-
ported that Down syndrome and elective admission
were associated with lower odds of mortality, when eval-
uating the risk of death in more than 10,200 hospitaliza-
tions for pediatric cardiac surgery within the Healthcare
Cost and Utilization Project Kids’ inpatient database
for the year 2000 in the United States. On the contrary,
VACTERL syndrome was associated with higher odds
of mortality in our cohort, mainly because of infective
complications. CHARGE, Noonan, Alagille, and Can-
trell syndrome were associated with suboptimal 5-year
survival.
3. Freedom from reintervention in syndromic CTHD was
significantly lower compared with nonsyndromic pa-
tients. Residual RVOT obstruction was the dominant in-
dication for reintervention or interventional procedures in
the syndromic subgroup. Central PA hypoplasia and
more frequent use of palliative procedures in syndromic
CTHD can account for a higher incidence of recurrent
RVOTO or branch PA stenosis after cardiac repair.
4. Primary and staged repair of CTHD allowed similar 15-
year survival. This finding is interesting because the co-
hort includes patients who achieved a 2-ventricle repair,
therefore excluding interstage attrition. Because there
was no significant difference in surgical strategy based
on genotype, we speculate that primary cardiac repair
could be accomplished even in syndromic patients,
whenever a favorable anatomic cardiac phenotype is
documented. We suggest that anatomy, not genetics,ardiovascular Surgery c Volume 138, Number 3 569
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CTHD repair, despite the absolute higher mortality and
morbidity observed in syndromic patients.
Study Limitations
This retrospective study has several limitations. In the ab-
sence of a randomized study, it could be argued that pallia-
tive procedures were selected for higher risk patients, such
as syndromic patients with extracardiac comorbidities or
less favorable anatomic patterns, introducing a selection
bias in the analysis. Moreover, patterns of surgical treatment
of CTHDs might be different at other institutions. This study
does not exclude the impact of other anatomic predictors of
early mortality that could not be evaluated because of the
size of this cohort (ie, truncus IAA). The surgical technique
was clearly tailored to the individual anatomy; however, pa-
tients with less favorable outcome, such as those with tri-
somy 13 or 18, were excluded from this study. The cohort
included patients who achieved 2-ventricle repair, neutraliz-
ing the impact of palliative procedures on surgical mortality.
No statistical difference was documented when comparing
surgical strategy in syndromic versus nonsyndromic
CTHD. There was no correlation between surgical strategy
of primary or staged cardiac repair and presence or absence
of extracardiac lesions requiring extracardiac surgery. In
other words, there was not a selective bias for palliative pro-
cedures in higher risk patients with genetic syndrome or ex-
tracardiac comorbidities.
CONCLUSIONS
del22q11 and trisomy 21 do not represent risk factors for
mortality after repair of conotruncal anomalies, whereas other
syndromes, particularly VACTERL syndrome, adversely af-
fect the surgical outcome for predominant noncardiac attrition.
Higher morbidity and lower mid-term freedom from reinter-
vention can be predicted in syndromic patients with CTHDs.
We recognize the technical assistance and expertise of DrMarina
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Michielon et al Congenital Heart DiseaseTABLE E1. Contingency table plotting type of genetic syndrome versus cardiac anatomy
Syndrome
No syndrome del22q11 (%) Trisomy 21 (%) VACTERL (%) Other (%) Totals (%)
TOF 418 (77.4) 36 (6.7) 26 (4.8) 16 (2.9) 44 (8.2) 540 (100)
TOF-PA 44 (75.9) 5 (8.6) 1 (1.7) 0 8 (13.8) 58 (100)
TOF-PA-MAPCAs 39 (61.9) 21 (33.4) 0 0 3 (4.7) 63 (100)
Truncus 29 (64.4) 11 (24.5) 0 0 5 (11.1) 45 (100)
DORV 30 (66.7) 3 (6.7) 1 (2.2) 0 11 (24.4) 45 (100)
IAA 16 (44.4) 15 (41.7) 1 (2.7) 2 (5.6) 2 (5.6) 36 (100)
Totals 576 (73.1) 91 (11.6) 29 (3.7) 18 (2.3) 73 (9.3) 787 (100)TABLE E2. Causes of death in syndromic and nonsyndromic patients
Syndrome No syndrome
Cardiac
Low cardiac output 8 18
Diastolic RV dysfunction 8 7
Residual hemodynamic defect 7 7
Pulmonary vascular disease 1
Pulmonary vein lesion 1
Lobar PA branch
lesion (catheter laboratory)
1
Pulmonary reperfusion injury 1
Arrhythmia 2 4
Noncardiac
Sepsis 7 4
Mediastinitis 2 1
Enterocolitis 1
Respiratory failure 1
Hepatic failure 1
Airway bleeding 3
Cerebral event 2 3The Journal of Thoracic and CarTABLE E3. Univariate logistic regression model coefficient table for
mortality
Coefficient Chi-square R P value OR
Age (mo) 0.008 0.027 0.0 .96 0.99
Weight 0.28 0.06 0.0 .8 1.0
Sex: male 0.024 0.01 0.0 .9 0.97
Genetic syndrome 1.36 24.2 0.2 <.0001 3.91
Del22q11 1.1 16.8 0.18 .008 0.21
Trisomy 21 1.4 26.5 0.23<.001 0.16
VACTERL 1.22 17.53 0.24 .013 2.81
Non-TOF diagnosis 1.43 39.8 0.26<.0001 4.18
Extracardiac surgery 1.09 13.4 0.14 .0002 2.99
PA hypoplasia 1.18 12.5 0.16<.001 3.2
Anomalous systemic
venous connection
0.49 5.6 .08 0.04 1.48
Discontinuous PAs 1.02 11 0.12 .022 2.89
Multiple VSDs 0.61 2.07 0.07 .15 1.4
Anomalous coronary pattern 0.21 1.8 0.04 .66 1.25
Conal septal hypoplasia 0.71 2.7 0.08 .045 1.8
Staged repair 0.44 1.9 0.06 0.18 1.35
Associated cardiac procedure 0.84 12.7 0.13 .004 2.3
R, Partial correlation coefficient; OR, odds ratio.diovascular Surgery c Volume 138, Number 3 570.e1
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Congenital Heart Disease Michielon et alTABLE E4. Cox proportional hazard multivariate analysis for
mortality
Coefficient Chi-square P value OR
Genetic syndrome 0.76 9.9 .016 2.14
Non-TOF diagnosis 1.067 18.3 <.001 2.9
Global null hypothesis tests for
mortality. Proportional
hazard model
Likelihood ratio test 28.1 <.001
OR, Odds ratio.TABLE E5. Depiction of patients with ‘‘other syndromes’’ stratified by anatomic subtypes
TOF TOF-PA TOF-PA-MAPCAs DORV TA IAA 5-y survival
CHARGE 7 4 0 3 1 0 58.3%  16.1%
Noonan 7 0 0 2 2 0 62.5%  21.3%
Alagille 4 0 0 0 0 0 54.7%  18.4%
Cantrell 2 0 2 2 0 0 23.3%  21.2%
Kabuki 2 0 0 3 0 0 100%
Klippel Feil 2 2 0 0 0 0 81%  11.5%
Turner 1 0 0 0 0 1 100%
Opitz 3 0 0 0 0 0 80%  14%
Williams 2 0 0 0 0 1 71%  14%
Torell 1 0 0 0 0 0 100%
Goldenhar 2 1 0 0 0 0 80%  15%
Sotos 1 0 0 0 0 0 100%
Waardenburg 1 0 0 0 0 0 100%
Townes-Brocks 0 0 1 0 0 0 100%
Cystic fibrosis 1 0 0 0 0 0 0%
Del 5 p syndrome 1 0 0 0 0 0 100%
Del 8 p syndrome 1 0 0 0 0 0 100%
Del 10 p syndrome 1 0 0 0 1 0 100%
Residual br arch 1 0 0 0 0 0 100%
Mosaic trisomy 22 1 1 0 0 0 0 100%
Translocation 21/17 1 0 0 0 0 0 100%
Chrom 7 anomalies 1 0 0 0 0 0 100%
Duplication 18q 1 0 0 1 0 0 100%
Trisomy 8 mosaic 0 0 0 0 0 1 100%
Totals 44 8 3 11 5 2 75.1%  11.8%
Five-year survival is reported.570.e2 The Journal of Thoracic and Cardiovascular Surgery c September 2009
